Forecasting The Future: 11 Analyst Projections For Exelixis
During the last three months, 11 analysts shared their evaluations of Exelixis (NASDAQ:EXEL), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 7 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 0 | 5 | 0 | 0 |
| 2M Ago | 2 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $47.18, with a high estimate of $54.00 and a low estimate of $35.00. Surpassing the previous average price target of $45.45, the current average has increased by 3.81%.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Leonid Timashev | RBC Capital | Lowers | Sector Perform | $43.00 | $46.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $54.00 | $52.00 |
| Leonid Timashev | RBC Capital | Raises | Sector Perform | $46.00 | $45.00 |
| Stephen Willey | Stifel | Raises | Hold | $44.00 | $43.00 |
| Eva Fortea Verdejo | Wells Fargo | Raises | Equal-Weight | $35.00 | $30.00 |
| Etzer Darout | Barclays | Raises | Equal-Weight | $44.00 | $41.00 |
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $52.00 | $52.00 |
| Sean Laaman | Morgan Stanley | Raises | Equal-Weight | $49.00 | $48.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $52.00 | $49.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $52.00 | $49.00 |
| Sean Laaman | Morgan Stanley | Raises | Equal-Weight | $48.00 | $45.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Exelixis compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exelixis's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Exelixis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Exelixis analyst ratings.
Delving into Exelixis's Background
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Breaking Down Exelixis's Financial Performance
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Exelixis's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 10.79%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's net margin excels beyond industry benchmarks, reaching 32.38%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Exelixis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 7.04%, the company showcases effective utilization of assets.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.